Dirucotide (MBP 8298) is a synthetic myelin basic protein (MBP) peptide designed to decrease type 2 helper T cells (TH2)-mediated B-cell signalling of auto-reactive T-cells thereby reducing the production of specific antibodies that target endogenous MBP. MBP is the dominant site of attack in patients with multiple sclerosis and haplotype (HLA) DR2 or DR4. Dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS), during the two-year MAESTRO-01 Phase III trial in patients with secondary progressive multiple sclerosis (SPMS). In addition, there were no statistically significant differences between dirucotide and placebo on the secondary endpoints of the study. After disappointing trial results, development of the drug was ended in 2009.
Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Mon Mar 31 21:00:45 GMT 2025
by
admin
on
Mon Mar 31 21:00:45 GMT 2025
|
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
26188K0CWH
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
152074-97-0
Created by
admin on Mon Mar 31 21:00:45 GMT 2025 , Edited by admin on Mon Mar 31 21:00:45 GMT 2025
|
PRIMARY | |||
|
TT-106
Created by
admin on Mon Mar 31 21:00:45 GMT 2025 , Edited by admin on Mon Mar 31 21:00:45 GMT 2025
|
PRIMARY | |||
|
m4666
Created by
admin on Mon Mar 31 21:00:45 GMT 2025 , Edited by admin on Mon Mar 31 21:00:45 GMT 2025
|
PRIMARY | Merck Index | ||
|
26188K0CWH
Created by
admin on Mon Mar 31 21:00:45 GMT 2025 , Edited by admin on Mon Mar 31 21:00:45 GMT 2025
|
PRIMARY | |||
|
DIRUCOTIDE
Created by
admin on Mon Mar 31 21:00:45 GMT 2025 , Edited by admin on Mon Mar 31 21:00:45 GMT 2025
|
PRIMARY | |||
|
9014
Created by
admin on Mon Mar 31 21:00:45 GMT 2025 , Edited by admin on Mon Mar 31 21:00:45 GMT 2025
|
PRIMARY | |||
|
DB04921
Created by
admin on Mon Mar 31 21:00:45 GMT 2025 , Edited by admin on Mon Mar 31 21:00:45 GMT 2025
|
PRIMARY | |||
|
DTXSID101336603
Created by
admin on Mon Mar 31 21:00:45 GMT 2025 , Edited by admin on Mon Mar 31 21:00:45 GMT 2025
|
PRIMARY | |||
|
SUB79317
Created by
admin on Mon Mar 31 21:00:45 GMT 2025 , Edited by admin on Mon Mar 31 21:00:45 GMT 2025
|
PRIMARY | |||
|
100000138900
Created by
admin on Mon Mar 31 21:00:45 GMT 2025 , Edited by admin on Mon Mar 31 21:00:45 GMT 2025
|
PRIMARY | |||
|
44151255
Created by
admin on Mon Mar 31 21:00:45 GMT 2025 , Edited by admin on Mon Mar 31 21:00:45 GMT 2025
|
PRIMARY | |||
|
CHEMBL2105639
Created by
admin on Mon Mar 31 21:00:45 GMT 2025 , Edited by admin on Mon Mar 31 21:00:45 GMT 2025
|
PRIMARY | |||
|
C166542
Created by
admin on Mon Mar 31 21:00:45 GMT 2025 , Edited by admin on Mon Mar 31 21:00:45 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET->TOLEROGEN |
Developed for the treatment of Multiple Sclerosis (MS). Did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS), during the two-year MAESTRO-01 Phase III trial in patients with secondary progressive multiple sclerosis (SPMS).
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Molecular Formula | CHEMICAL |
|
||||
| MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|